{"chatcmpl-9ALbxPL1dFBz1PnWgwRGbA5XXVZ8n": {"usage_dict": {"completion_tokens": 81, "prompt_tokens": 1386, "total_tokens": 1467}, "data_dict": {"PMID37256976": [{"drug name": "capivasertib", "target": [{"direct target": "AKT", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": ["NCT04305496"]}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALc00y8DQWDaDcUlccb6c6BwA9dy": {"usage_dict": {"completion_tokens": 88, "prompt_tokens": 1402, "total_tokens": 1490}, "data_dict": {"PMID37070653": [{"drug name": "camizestrant", "target": [{"direct target": "ESR1", "drug-direct target interaction": "selective estrogen receptor degrader (SERD)"}], "tested or effective group": ["ESR1 mutation (ESR1m)"], "drug tested in following diseases": ["advanced breast cancer", "HR+/HER2- ABC"], "ClinicalTrials.gov ID": ["NCT04964934"]}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALc60zRPUnEaEICzRPGnAqrGVtnQ": {"usage_dict": {"completion_tokens": 69, "prompt_tokens": 1040, "total_tokens": 1109}, "data_dict": {"PMID37147285": [{"drug name": "Z839878730", "target": [{"direct target": "KK-LC-1", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["TNBC ALDH+ cells"], "drug tested in following diseases": ["triple negative breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcBBOMqs6mF6TPwXkeMrBj7Z6PE": {"usage_dict": {"completion_tokens": 59, "prompt_tokens": 995, "total_tokens": 1054}, "data_dict": {"PMID37723305": [{"drug name": null, "target": [{"direct target": "ACSS2", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["breast cancer models"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcFuaYe1CFLrKl4AYOGK9hNbilZ": {"usage_dict": {"completion_tokens": 132, "prompt_tokens": 1040, "total_tokens": 1172}, "data_dict": {"PMID36585452": [{"drug name": "ricolinostat", "target": [{"direct target": "HDAC6", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["HR+/HER2- breast cancer"], "drug tested in following diseases": ["breast cancer", "metastatic breast cancer"], "ClinicalTrials.gov ID": ["NCT02632071"]}, {"drug name": "nab-paclitaxel", "target": [], "tested or effective group": ["HR+/HER2- breast cancer"], "drug tested in following diseases": ["breast cancer", "metastatic breast cancer"], "ClinicalTrials.gov ID": ["NCT02632071"]}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcMNTxQbqgwmVvn9z4NkWGPzCVa": {"usage_dict": {"completion_tokens": 105, "prompt_tokens": 955, "total_tokens": 1060}, "data_dict": {"PMID37343696": [{"drug name": "EGFR/mTOR inhibitor", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["TNBC"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": []}, {"drug name": "AKT inhibitor", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["TNBC"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcTQR7VH0Z71HwDUIO1yJF6RZwt": {"usage_dict": {"completion_tokens": 66, "prompt_tokens": 976, "total_tokens": 1042}, "data_dict": {"PMID36908287": [{"drug name": "sacituzumab govitecan", "target": [], "tested or effective group": ["hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcX5hhIsbcXww6aVVFcjfsZuqSu": {"usage_dict": {"completion_tokens": 63, "prompt_tokens": 975, "total_tokens": 1038}, "data_dict": {"PMID37103085": [{"drug name": "13-Oxo-ODE", "target": [{"direct target": "c-Myc", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["BCSCs"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcbBpiKgcsnFhruMNkmVy2TBP7D": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 984, "total_tokens": 992}, "data_dict": {"PMID37916184": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcc1P9LXfUTFPnF7USz0QJlXcJJ": {"usage_dict": {"completion_tokens": 121, "prompt_tokens": 1149, "total_tokens": 1270}, "data_dict": {"PMID37326467": [{"drug name": "fulvestrant", "target": [{"direct target": "ER", "drug-direct target interaction": "selective estrogen receptor degrader"}], "tested or effective group": ["ER-positive breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "abemaciclib", "target": [{"direct target": "CDK4/6", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["ER-positive breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALciUNgsj8FZmtNGZkJG7zaA34Mu": {"usage_dict": {"completion_tokens": 60, "prompt_tokens": 1073, "total_tokens": 1133}, "data_dict": {"PMID36841821": [{"drug name": "S62", "target": [{"direct target": "PELI1/EGFR", "drug-direct target interaction": "disruptor"}], "tested or effective group": ["null"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcl4BLM1hba610CFU6kqNLSUrlL": {"usage_dict": {"completion_tokens": 111, "prompt_tokens": 946, "total_tokens": 1057}, "data_dict": {"PMID37234088": [{"drug name": "Cdk4/6 inhibitors", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["ER+ breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "fulvestrant", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["ER+ breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcrR7sVUB2C6sGsyoVp3MWokrlT": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 785, "total_tokens": 793}, "data_dict": {"PMID38192413": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALcshXt8FJ4m3KQ9bLXMyeyRBaMW": {"usage_dict": {"completion_tokens": 174, "prompt_tokens": 1121, "total_tokens": 1295}, "data_dict": {"PMID36791497": [{"drug name": "Osimertinib", "target": [{"direct target": "EGFR", "drug-direct target interaction": "tyrosine kinase inhibitor"}], "tested or effective group": ["EGFR L858R point mutations in Exon 21", "EGFR T790M"], "drug tested in following diseases": ["non-small cell lung cancer", "NSCLC"], "ClinicalTrials.gov ID": null}, {"drug name": "ER121", "target": [{"direct target": "erbB2/HER2", "drug-direct target interaction": "kinase inhibitor"}, {"direct target": "EGFR C797S", "drug-direct target interaction": "kinase inhibitor"}], "tested or effective group": ["EGFR T790M", "EGFR C797S mutations", "amplified ErbB2"], "drug tested in following diseases": ["human cancers"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALd3NaYgLGvVTmbeXJiTRJn6Nz5M": {"usage_dict": {"completion_tokens": 113, "prompt_tokens": 1115, "total_tokens": 1228}, "data_dict": {"PMID36702335": [{"drug name": "BIC-113", "target": [{"direct target": "AEP", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["breast cancer bone metastasis"], "drug tested in following diseases": ["breast cancer", "bone metastasis"], "ClinicalTrials.gov ID": null}, {"drug name": "epirubicin", "target": [], "tested or effective group": ["breast cancer bone metastasis"], "drug tested in following diseases": ["breast cancer", "bone metastasis"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALd9lvRbUTDMpzit0FNjjOYXMmUA": {"usage_dict": {"completion_tokens": 132, "prompt_tokens": 1212, "total_tokens": 1344}, "data_dict": {"PMID36889811": [{"drug name": "trastuzumab", "target": [{"direct target": "HER2", "drug-direct target interaction": "antibody"}], "tested or effective group": ["HER2+ breast cancer", "MUC4+ breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "DN", "target": [{"direct target": "sTNF\u03b1", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["HER2+ breast cancer", "MUC4+ breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALdEBv2Z66qlZ0704p3ma4528dvz": {"usage_dict": {"completion_tokens": 100, "prompt_tokens": 1123, "total_tokens": 1223}, "data_dict": {"PMID37264081": [{"drug name": "RMC-6272", "target": [{"direct target": "mTORC1", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["ER+/HER2- breast cancer cell lines with PIK3CA or PTEN mutations", "hormone therapy-resistant acquired cell lines", "CDK4/6 inhibitor treated acquired resistant cell lines"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALdJvGJ3E8kUAJ3PIvLk5LXBSwRG": {"usage_dict": {"completion_tokens": 76, "prompt_tokens": 1109, "total_tokens": 1185}, "data_dict": {"PMID36909163": [{"drug name": "ASR490", "target": [{"direct target": "Notch1", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["BCSCs (ALDH+ and CD44+/CD24-)", "breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALdOTba0eeCiSZEdxHrf1XbVYMlQ": {"usage_dict": {"completion_tokens": 229, "prompt_tokens": 1116, "total_tokens": 1345}, "data_dict": {"PMID36926455": [{"drug name": "Palbociclib", "target": [], "tested or effective group": null, "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "Panobinostat", "target": [], "tested or effective group": null, "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "PD-0325901", "target": [], "tested or effective group": null, "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "PLX4720", "target": [], "tested or effective group": null, "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "Selumetinib", "target": [], "tested or effective group": null, "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "Tanespimycin", "target": [], "tested or effective group": null, "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALdWMKsQXqKwH2YAsheg8pf1tP7j": {"usage_dict": {"completion_tokens": 75, "prompt_tokens": 1138, "total_tokens": 1213}, "data_dict": {"PMID37585496": [{"drug name": "AZD1390", "target": [{"direct target": "ataxia-telangiectasia mutated", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["DNA damage response gene mutations"], "drug tested in following diseases": ["central nervous system metastasis", "breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALdZA9Enry4uRif5xELfwNg9IuFw": {"usage_dict": {"completion_tokens": 67, "prompt_tokens": 1048, "total_tokens": 1115}, "data_dict": {"PMID37141396": [{"drug name": "pralsetinib", "target": [{"direct target": "RET", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["CCDC6-RET fusion"], "drug tested in following diseases": ["TNBC", "breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALdcxLgAfNYpCb959aUddOcyguAQ": {"usage_dict": {"completion_tokens": 171, "prompt_tokens": 1231, "total_tokens": 1402}, "data_dict": {"PMID36945886": [{"drug name": "ribociclib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["metastatic breast cancer"], "drug tested in following diseases": ["metastatic breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "palbociclib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["metastatic breast cancer"], "drug tested in following diseases": ["metastatic breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "abemaciclib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["metastatic breast cancer"], "drug tested in following diseases": ["metastatic breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALdrsYpBLixBWX7KRNca1Mre3B72": {"usage_dict": {"completion_tokens": 107, "prompt_tokens": 1012, "total_tokens": 1119}, "data_dict": {"PMID37128608": [{"drug name": "decitabine", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["TNBC"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "glucocorticoid", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["TNBC"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALe1EvxVnPwzFtfHiM7H14fzeolE": {"usage_dict": {"completion_tokens": 137, "prompt_tokens": 1045, "total_tokens": 1182}, "data_dict": {"PMID37044095": [{"drug name": "alpelisib", "target": [{"direct target": "PI3K\u03b1", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["PIK3CAH1047R mutated breast cancer", "NF1 loss breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "N-acetylcysteine", "target": [{"direct target": "NF1 knockout cells", "drug-direct target interaction": "sensitizer"}], "tested or effective group": ["NF1 loss breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALe6ggUA8SEVFnlCeqSs9O8PnsZ9": {"usage_dict": {"completion_tokens": 123, "prompt_tokens": 1086, "total_tokens": 1209}, "data_dict": {"PMID37071495": [{"drug name": "pralsetinib", "target": [{"direct target": "RET", "drug-direct target interaction": "selective RET inhibitor"}], "tested or effective group": ["ESR1-TAF-driven ET-resistant"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "palbociclib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["ESR1-TAF-driven ET-resistant"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeC0b0nwPiQKXRybGuhEKgpBkoJ": {"usage_dict": {"completion_tokens": 61, "prompt_tokens": 1164, "total_tokens": 1225}, "data_dict": {"PMID37323664": [{"drug name": "Fluorouracil", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": null, "drug tested in following diseases": ["liver cancer", "breast cancer"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeGOAhq7MIq4ti4BBHhY2e08pVE": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 1231, "total_tokens": 1239}, "data_dict": {"PMID37529698": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeIZcUSOrLwfbRLmahx4Ls64kIT": {"usage_dict": {"completion_tokens": 78, "prompt_tokens": 1191, "total_tokens": 1269}, "data_dict": {"PMID38362162": [{"drug name": "Tunicamycin-P", "target": [{"direct target": "N-acetylglusosaminyl 1-phosphate transferase", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["breast cancer of all subtypes"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeRn7rTb0RInVNjogliBX1iRzEu": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 1021, "total_tokens": 1029}, "data_dict": {"PMID37091185": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeStW6Cl1Rw79Hzm48tlHyg3Hmn": {"usage_dict": {"completion_tokens": 138, "prompt_tokens": 1105, "total_tokens": 1243}, "data_dict": {"PMID37099721": [{"drug name": "NQO1-SN38", "target": [{"direct target": "NQO1", "drug-direct target interaction": "TME-responsive drug"}], "tested or effective group": ["NAD(P)H quinone oxidoreductase 1 overexpressed breast cancer"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "BAPN", "target": [{"direct target": "Lox", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["breast cancer with tumor stiffness"], "drug tested in following diseases": ["breast cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeXBUZWHZSiQ11sUTNuDAwXDuMh": {"usage_dict": {"completion_tokens": 55, "prompt_tokens": 973, "total_tokens": 1028}, "data_dict": {"PMID36657446": [{"drug name": null, "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["patients with advanced lung cancer"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALec8keN9A7fQgArFq8ncwTcw3JP": {"usage_dict": {"completion_tokens": 69, "prompt_tokens": 1207, "total_tokens": 1276}, "data_dict": {"PMID36932427": [{"drug name": "STM2457", "target": [{"direct target": "METTL3", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["chemoresistant SCLC"], "drug tested in following diseases": ["small cell lung cancer", "SCLC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALei3Q7aYFGXEI9j9VeykUXrU5UN": {"usage_dict": {"completion_tokens": 68, "prompt_tokens": 1070, "total_tokens": 1138}, "data_dict": {"PMID37407818": [{"drug name": null, "target": [{"direct target": "APOBEC3A", "drug-direct target interaction": "suppression"}], "tested or effective group": ["drug-tolerant cancer cells"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALenJB1ThrrrBTM2gkDhz6Gs7fz1": {"usage_dict": {"completion_tokens": 67, "prompt_tokens": 1214, "total_tokens": 1281}, "data_dict": {"PMID37061993": [{"drug name": "IACS-010759", "target": [{"direct target": "OXPHOS", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["TKI-resistant non-small cell lung cancer"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeqZJGXv1aMLtB4SlyWfrtGZdN8": {"usage_dict": {"completion_tokens": 78, "prompt_tokens": 1171, "total_tokens": 1249}, "data_dict": {"PMID37321064": [{"drug name": "MAM", "target": [{"direct target": "NQO1", "drug-direct target interaction": "activator"}], "tested or effective group": ["cisplatin-resistant A549", "AZD9291-resistant H1975"], "drug tested in following diseases": ["non-small cell lung cancer", "NSCLC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALetgRDLRdM1f42ZNRRc1UMCjgaH": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 1023, "total_tokens": 1031}, "data_dict": {"PMID36574773": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALeu9H7z51dMlQjQRC3Nls4M1XDr": {"usage_dict": {"completion_tokens": 110, "prompt_tokens": 1081, "total_tokens": 1191}, "data_dict": {"PMID37269335": [{"drug name": "PF-07284892", "target": [{"direct target": "SHP2", "drug-direct target interaction": "allosteric inhibitor"}], "tested or effective group": ["ALK fusion-positive lung cancer", "BRAFV600E-mutant colorectal cancer", "KRASG12D-mutant ovarian cancer", "ROS1 fusion-positive pancreatic cancer"], "drug tested in following diseases": ["lung cancer", "colorectal cancer", "ovarian cancer", "pancreatic cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALf1CzZUU7npdIAmXu5OELTGqm8Q": {"usage_dict": {"completion_tokens": 118, "prompt_tokens": 1134, "total_tokens": 1252}, "data_dict": {"PMID37831007": [{"drug name": "sotorasib", "target": [{"direct target": "KRASG12C", "drug-direct target interaction": "inhibitor"}], "tested or effective group": null, "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "MRTX1133", "target": [{"direct target": "KRASG12D", "drug-direct target interaction": "inhibitor"}], "tested or effective group": null, "drug tested in following diseases": ["PDAC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALf6xjlaMmQxWyuH5fHc0D4QTiy8": {"usage_dict": {"completion_tokens": 70, "prompt_tokens": 1079, "total_tokens": 1149}, "data_dict": {"PMID36444143": [{"drug name": "Trastuzumab deruxtecan", "target": [{"direct target": "HER2", "drug-direct target interaction": "targeted agent"}], "tested or effective group": ["HER2-mutant NSCLC"], "drug tested in following diseases": ["NSCLC"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfAus9dd618vIOtuDieYJP549kh": {"usage_dict": {"completion_tokens": 166, "prompt_tokens": 1129, "total_tokens": 1295}, "data_dict": {"PMID36240971": [{"drug name": "TAK-228", "target": [{"direct target": "TORC1/2", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["NFE2L2-mutated LUSC", "KEAP1-mutated LUSC", "KRAS/NFE2L2- or KEAP1-mutated NSCLC"], "drug tested in following diseases": ["NSCLC", "LUSC"], "ClinicalTrials.gov ID": null}, {"drug name": "CB-839", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["NFE2L2-mutated LUSC"], "drug tested in following diseases": ["NSCLC", "LUSC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfHLBCSxbzVSQLZcECXkVDP3yY5": {"usage_dict": {"completion_tokens": 212, "prompt_tokens": 1040, "total_tokens": 1252}, "data_dict": {"PMID37831779": [{"drug name": "sotorasib", "target": [{"direct target": "KRAS", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["inherently resistant NSCLC", "acquired resistant NSCLC"], "drug tested in following diseases": ["NSCLC"], "ClinicalTrials.gov ID": null}, {"drug name": "carfilzomib", "target": [{"direct target": "ITGB4", "drug-direct target interaction": "down-regulator"}, {"direct target": "\u03b2-catenin", "drug-direct target interaction": "down-regulator"}], "tested or effective group": ["inherently resistant NSCLC", "acquired resistant NSCLC"], "drug tested in following diseases": ["NSCLC"], "ClinicalTrials.gov ID": null}, {"drug name": "adagrasib", "target": [{"direct target": "KRAS", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["inherently resistant NSCLC"], "drug tested in following diseases": ["NSCLC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfRKibNXYrW5X437fOkfQE8IKVy": {"usage_dict": {"completion_tokens": 72, "prompt_tokens": 1171, "total_tokens": 1243}, "data_dict": {"PMID36948246": [{"drug name": "D-1553", "target": [{"direct target": "KRAS G12C", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["KRAS G12C-mutated NSCLC"], "drug tested in following diseases": ["NSCLC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfUctUZnBqO3bpQj8E2ugXQQhqd": {"usage_dict": {"completion_tokens": 177, "prompt_tokens": 1053, "total_tokens": 1230}, "data_dict": {"PMID36811415": [{"drug name": "savolitinib", "target": [{"direct target": "MET", "drug-direct target interaction": "tyrosine kinase inhibitor"}], "tested or effective group": ["NSCLC with MET ex 14 skipping mutation", "EGFR-mutant MET with progression during first-line EGFR-TKI treatment"], "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "osimertinib", "target": [], "tested or effective group": ["advanced EGFR-mutated NSCLC, initially with MET expression"], "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "gefitinib", "target": [], "tested or effective group": [], "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfco070KzQaCNippwJOyBi9jdde": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 785, "total_tokens": 793}, "data_dict": {"PMID37350939": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfdwMDhrRjO8FlAaQOOVyyFc3U0": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 971, "total_tokens": 979}, "data_dict": {"PMID37151885": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfe6sAxy4CZUEGb5JAOm18SPJUb": {"usage_dict": {"completion_tokens": 133, "prompt_tokens": 1069, "total_tokens": 1202}, "data_dict": {"PMID36650267": [{"drug name": "KU60019", "target": [{"direct target": "ATM", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["lung cancer cell lines H1299 and A549"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "VP-16", "target": [{"direct target": "TOP2", "drug-direct target interaction": "poison"}], "tested or effective group": ["lung cancer cell lines H1299 and A549"], "drug tested in following diseases": ["lymphomas", "leukemias", "lung cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfjWowONOmfNh191X1pARk3mBjW": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 1047, "total_tokens": 1055}, "data_dict": {"PMID36821441": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALfkK9GZ3twN5gvOUR9uyJ1uurXo": {"usage_dict": {"completion_tokens": 230, "prompt_tokens": 1069, "total_tokens": 1299}, "data_dict": {"PMID37491889": [{"drug name": "lurbinectedin", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["MYC-driven non-neuroendocrine SCLC"], "drug tested in following diseases": ["SCLC"], "ClinicalTrials.gov ID": ["NCT04802174"]}, {"drug name": "berzosertib", "target": [{"direct target": "ATR", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["MYC-driven non-neuroendocrine SCLC"], "drug tested in following diseases": ["SCLC"], "ClinicalTrials.gov ID": ["NCT04802174"]}, {"drug name": "lurbinectedin-berzosertib combination", "target": [{"direct target": "ATR", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["MYC-driven non-neuroendocrine SCLC", "high CDKN1A/p21 expression", "increased levels of ERCC5/XPG"], "drug tested in following diseases": ["SCLC"], "ClinicalTrials.gov ID": ["NCT04802174"]}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALg0ImOJX2in9uQzc9SlbVXzUqiL": {"usage_dict": {"completion_tokens": 168, "prompt_tokens": 1003, "total_tokens": 1171}, "data_dict": {"PMID36961816": [{"drug name": "EGF816", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["EGFR-mutant lung cancer"], "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "ceritinib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["ALK inhibitor in non-small cell lung cancer"], "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "dasatinib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": null, "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALg8dcLI12TqnxtNX5Ad6h3RQeyT": {"usage_dict": {"completion_tokens": 58, "prompt_tokens": 1070, "total_tokens": 1128}, "data_dict": {"PMID37507782": [{"drug name": "sertaconazole", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["lung cancer xenograft models"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgC61708IdQPXB3zIkI72UKAEwY": {"usage_dict": {"completion_tokens": 79, "prompt_tokens": 1164, "total_tokens": 1243}, "data_dict": {"PMID36942434": [{"drug name": "osimertinib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["patients with metastatic non-small cell lung cancer harbouring sensitising"], "drug tested in following diseases": ["non-small cell lung cancer", "adenocarcinoma of the lung"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgGy5mNUnLib7iWoEG8yn0BeUa3": {"usage_dict": {"completion_tokens": 197, "prompt_tokens": 1019, "total_tokens": 1216}, "data_dict": {"PMID36414681": [{"drug name": "sotorasib", "target": [{"direct target": "KRAS-G12C", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["KRAS-G12C mutated"], "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "adagrasib", "target": [{"direct target": "KRAS-G12C", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["KRAS-G12C mutated"], "drug tested in following diseases": ["non-small cell lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "MRTX1133", "target": [{"direct target": "KRAS-G12D", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["KRAS-G12D bearing"], "drug tested in following diseases": ["pancreatic ductal adenocarcinoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgOxvmuEc2GR59Q57RaFeDkT21a": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 940, "total_tokens": 948}, "data_dict": {"PMID36196556": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgPU6k7rHVTIMD5Gb5wNcmCQLfZ": {"usage_dict": {"completion_tokens": 64, "prompt_tokens": 1094, "total_tokens": 1158}, "data_dict": {"PMID36827714": [{"drug name": "C18", "target": [{"direct target": "MTHFD2", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["NSCLC"], "drug tested in following diseases": ["lung cancer", "NSCLC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgS190Kc0KVjjrX5Djql1dLjdFa": {"usage_dict": {"completion_tokens": 150, "prompt_tokens": 1075, "total_tokens": 1225}, "data_dict": {"PMID37816716": [{"drug name": "PKC inhibitors", "target": [{"direct target": "AURKB", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["KRAS-mutated lung cancers"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "MEK1/2 inhibitors", "target": [], "tested or effective group": ["KRAS-mutated lung cancers"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": null}, {"drug name": "KRASG12C inhibitors", "target": [], "tested or effective group": ["KRAS-mutated lung cancers"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgZ9tBlix7YkHogiad4q63SxoEm": {"usage_dict": {"completion_tokens": 137, "prompt_tokens": 1067, "total_tokens": 1204}, "data_dict": {"PMID36970205": [{"drug name": "trametinib", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["KRAS-mutant NSCLC"], "drug tested in following diseases": ["non-small cell lung cancer", "NSCLC"], "ClinicalTrials.gov ID": null}, {"drug name": "IACS-010759", "target": [{"direct target": "mitochondrial complex I", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["KRAS-mutant NSCLC"], "drug tested in following diseases": ["non-small cell lung cancer", "NSCLC"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgeg0DYchI4wCWYjLVTG3my0U9j": {"usage_dict": {"completion_tokens": 62, "prompt_tokens": 1234, "total_tokens": 1296}, "data_dict": {"PMID36883602": [{"drug name": "dihydroartemisinin", "target": [{"direct target": "SERCA", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["lung cancer"], "drug tested in following diseases": ["lung cancer"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALghTUQoUL1kPqX7sc88l0oIuVi5": {"usage_dict": {"completion_tokens": 78, "prompt_tokens": 1039, "total_tokens": 1117}, "data_dict": {"PMID36791206": [{"drug name": "toosendanin", "target": [{"direct target": "Hck", "drug-direct target interaction": "interactor"}, {"direct target": "Lyn", "drug-direct target interaction": "interactor"}], "tested or effective group": ["GBM"], "drug tested in following diseases": ["glioblastoma", "solid tumors"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgnnnl9dBd1XQTJyufK9rZtGTXl": {"usage_dict": {"completion_tokens": 62, "prompt_tokens": 1036, "total_tokens": 1098}, "data_dict": {"PMID37451272": [{"drug name": null, "target": [{"direct target": "F3", "drug-direct target interaction": null}], "tested or effective group": ["SA-\u03b2Gal+ GBM cells"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgqEnwbutYSeTUGrwCLPbWS3eeC": {"usage_dict": {"completion_tokens": 62, "prompt_tokens": 1083, "total_tokens": 1145}, "data_dict": {"PMID36749723": [{"drug name": "Eltrombopag", "target": [{"direct target": "TFEB", "drug-direct target interaction": "inhibitor"}], "tested or effective group": null, "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgtSi9Kg82hBqylrQ72HzLBYdaV": {"usage_dict": {"completion_tokens": 61, "prompt_tokens": 1159, "total_tokens": 1220}, "data_dict": {"PMID37935665": [{"drug name": "GA-amide", "target": [{"direct target": "WDR1", "drug-direct target interaction": "promoter"}], "tested or effective group": ["glioma"], "drug tested in following diseases": ["glioma", "GBM"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALgwBk5t3PRC7dUG9heo0ZRO9wjT": {"usage_dict": {"completion_tokens": 68, "prompt_tokens": 1086, "total_tokens": 1154}, "data_dict": {"PMID36966152": [{"drug name": "fatostatin", "target": [{"direct target": "AKT/mTORC1/GPX4 signaling pathway", "drug-direct target interaction": "inhibitor"}], "tested or effective group": null, "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALh37U8JR2vrabyr4UZqgxhCw9y6": {"usage_dict": {"completion_tokens": 118, "prompt_tokens": 1034, "total_tokens": 1152}, "data_dict": {"PMID38215747": [{"drug name": "temozolomide", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["glioblastoma"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}, {"drug name": "vemurafenib", "target": [{"direct target": "BRAF", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["glioblastoma"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALh9AL42k9qmInIGPMNqQD81GsmS": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 1003, "total_tokens": 1011}, "data_dict": {"PMID36707509": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhAcw15taWra8Mv6HEoHyLd35g7": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 1132, "total_tokens": 1140}, "data_dict": {"PMID36853018": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhBCNv2quEReDHSxDxZYk7KJy4Q": {"usage_dict": {"completion_tokens": 56, "prompt_tokens": 1021, "total_tokens": 1077}, "data_dict": {"PMID37667051": [{"drug name": null, "target": [{"direct target": "TFPI2", "drug-direct target interaction": null}], "tested or effective group": ["GSCs"], "drug tested in following diseases": ["GBM"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhEGd6RNiYqav0Kvi7ZEVvLWvjj": {"usage_dict": {"completion_tokens": 78, "prompt_tokens": 1039, "total_tokens": 1117}, "data_dict": {"PMID36624090": [{"drug name": "AT7519", "target": [{"direct target": "CDK1/2", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["U87MG, U251, and patient-derived primary GBM cells"], "drug tested in following diseases": ["glioblastoma multiforme"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhJ8vJQwAieDY2xS8OOwsyIvsIq": {"usage_dict": {"completion_tokens": 63, "prompt_tokens": 1173, "total_tokens": 1236}, "data_dict": {"PMID37770937": [{"drug name": "oxamate", "target": [{"direct target": "LDHA", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["glioblastoma mouse model"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhMLsNsOMPJT1RcoIjjSKvkTq4D": {"usage_dict": {"completion_tokens": 161, "prompt_tokens": 1227, "total_tokens": 1388}, "data_dict": {"PMID36272139": [{"drug name": "EPIC-0412", "target": [{"direct target": "HOTAIR and EZH2", "drug-direct target interaction": "inhibitor"}, {"direct target": "ATF3-p-p65-HADC1 axis", "drug-direct target interaction": "epigenetic silencer"}], "tested or effective group": ["TMZ resistant GBM"], "drug tested in following diseases": ["Glioblastoma multiforme"], "ClinicalTrials.gov ID": null}, {"drug name": "Temozolomide", "target": [{"direct target": "MGMT", "drug-direct target interaction": "resistance target"}], "tested or effective group": ["TMZ resistant GBM"], "drug tested in following diseases": ["Glioblastoma multiforme"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhVmbfRvxGyU3bf6GJoDss4ZOOA": {"usage_dict": {"completion_tokens": 69, "prompt_tokens": 1131, "total_tokens": 1200}, "data_dict": {"PMID36399643": [{"drug name": "regorafenib", "target": [{"direct target": "autophagosome-lysosome fusion", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["GBM"], "drug tested in following diseases": ["glioblastoma multiforme"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhZhTmAL2KLJMBWbPOjdEekLUiG": {"usage_dict": {"completion_tokens": 89, "prompt_tokens": 1327, "total_tokens": 1416}, "data_dict": {"PMID35849035": [{"drug name": "depatuxizumab mafodotin", "target": [{"direct target": "EGFR", "drug-direct target interaction": "antibody-drug conjugate"}], "tested or effective group": ["EGFR-amp GBM", "EGFRvIII-mutant", "MGMT unmethylated"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhd458hCtUOHxinac6bVU8o0gVS": {"usage_dict": {"completion_tokens": 110, "prompt_tokens": 1264, "total_tokens": 1374}, "data_dict": {"PMID36521103": [{"drug name": "SurVaxM", "target": [{"direct target": "survivin", "drug-direct target interaction": "activator"}], "tested or effective group": ["nGBM"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": ["NCT02455557"]}, {"drug name": "temozolomide (TMZ)", "target": [], "tested or effective group": ["nGBM"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhj2EL1VRqdlN5sGJ8riWWRcwGm": {"usage_dict": {"completion_tokens": 66, "prompt_tokens": 1148, "total_tokens": 1214}, "data_dict": {"PMID37417769": [{"drug name": "ANG-TRP-PK1@DOX", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["GBM"], "drug tested in following diseases": ["glioblastoma multiforme"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhmvA10mj1QGjfiOzuNfNhjtEHr": {"usage_dict": {"completion_tokens": 64, "prompt_tokens": 1042, "total_tokens": 1106}, "data_dict": {"PMID36453577": [{"drug name": "stellettin B", "target": [{"direct target": "PI3K\u03b1", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["GBM"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALhpKJDrQRQV4DZwC4ik4h4gVwCs": {"usage_dict": {"completion_tokens": 105, "prompt_tokens": 1122, "total_tokens": 1227}, "data_dict": {"PMID36652537": [{"drug name": "YTX-7739", "target": [{"direct target": "SCD", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["patient-derived GBM stem-like cells"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}, {"drug name": "temozolomide", "target": [], "tested or effective group": null, "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALht7lDOMaG9DlIEfqq1KAJOSgMU": {"usage_dict": {"completion_tokens": 118, "prompt_tokens": 1093, "total_tokens": 1211}, "data_dict": {"PMID36696484": [{"drug name": "CB1158", "target": [{"direct target": "arginase-1", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["patients with glioblastoma"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}, {"drug name": "tadalafil", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["patients with glioblastoma"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALi1FflmFkDqZnzXCMz5szAQ1xBD": {"usage_dict": {"completion_tokens": 68, "prompt_tokens": 1095, "total_tokens": 1163}, "data_dict": {"PMID36732025": [{"drug name": "WDR5 inhibitors", "target": [{"direct target": "WDR5", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["SOX2-enriched, therapy-resistant niche"], "drug tested in following diseases": ["GBM"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALi4Ep11eqIeYHpp12kZhN3UkfZF": {"usage_dict": {"completion_tokens": 103, "prompt_tokens": 1210, "total_tokens": 1313}, "data_dict": {"PMID36652263": [{"drug name": "NCD38", "target": [{"direct target": "KDM1A", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["glioma stem cells"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}, {"drug name": "temozolomide", "target": null, "tested or effective group": null, "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALi8wU8ziRHbAJU6G5bIehZU6UbQ": {"usage_dict": {"completion_tokens": 73, "prompt_tokens": 1034, "total_tokens": 1107}, "data_dict": {"PMID38134929": [{"drug name": "RGX-202-01", "target": [{"direct target": "SLC6A8", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["TAMC-secreted creatine positive GBM"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiDeCSYb93SX6PIffvMTC4UMrZh": {"usage_dict": {"completion_tokens": 102, "prompt_tokens": 1132, "total_tokens": 1234}, "data_dict": {"PMID37036151": [{"drug name": "Eltrombopag", "target": [{"direct target": "TFEB", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["null"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": ["null"]}, {"drug name": "Temozolomide", "target": [], "tested or effective group": ["null"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": ["null"]}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiGyq4Xjce82IFTvYi0aW8Sb1aW": {"usage_dict": {"completion_tokens": 59, "prompt_tokens": 1099, "total_tokens": 1158}, "data_dict": {"PMID37066699": [{"drug name": "Aloe-emodin", "target": [{"direct target": null, "drug-direct target interaction": null}], "tested or effective group": ["GBM"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiKwQDj7QtAMqFCUTH5VfBdtiy0": {"usage_dict": {"completion_tokens": 67, "prompt_tokens": 1023, "total_tokens": 1090}, "data_dict": {"PMID36972629": [{"drug name": "ONC201", "target": [{"direct target": "DRD2", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["GBM stem-like cells"], "drug tested in following diseases": ["glioblastoma", "GBM"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiNhNwLsoTboAM0rskhbvrPrD5d": {"usage_dict": {"completion_tokens": 108, "prompt_tokens": 1078, "total_tokens": 1186}, "data_dict": {"PMID37460404": [{"drug name": "indocyanine green", "target": [{"direct target": "null", "drug-direct target interaction": "null"}], "tested or effective group": ["null"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": []}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiS3HkzWXdkcKMyW1zsit8WQ7bp": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 1004, "total_tokens": 1012}, "data_dict": {"PMID37244935": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiT3Ecl4wXyKPzAA4n2ho6ZAVBR": {"usage_dict": {"completion_tokens": 68, "prompt_tokens": 1050, "total_tokens": 1118}, "data_dict": {"PMID37886538": [{"drug name": "stiripentol", "target": [{"direct target": "LDHA", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["glioblastoma cell glycolysis"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiWeWNal9mr5mArjwlCyoPJ0XQ2": {"usage_dict": {"completion_tokens": 8, "prompt_tokens": 785, "total_tokens": 793}, "data_dict": {"PMID37672559": []}, "model_str": "gpt-4-0125-preview"}, "chatcmpl-9ALiXPuC8eAhf9TmKTCkJr4flRDzS": {"usage_dict": {"completion_tokens": 130, "prompt_tokens": 1111, "total_tokens": 1241}, "data_dict": {"PMID37147437": [{"drug name": "ganciclovir", "target": [{"direct target": "EZH2", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["HCMV-induced glioblastoma"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}, {"drug name": "temozolomide", "target": [{"direct target": "EZH2", "drug-direct target interaction": "inhibitor"}], "tested or effective group": ["HCMV-induced glioblastoma"], "drug tested in following diseases": ["glioblastoma"], "ClinicalTrials.gov ID": null}]}, "model_str": "gpt-4-0125-preview"}}